Personalized medicine is no longer a futuristic concept; it is a present reality driving the expansion of peptide and oligonucleotide CDMOs. As therapies become more targeted, the demand for small-batch, high-complexity peptide APIs is increasing exponentially. The peptide and oligonucleotide CDMO market has grown rapidly, expanding from $2.42 billion in 2025 to an expected $2.7 billion in 2026 at a CAGR of 11.9%[reference:43].
CDMOs are responding by building flexible manufacturing units capable of handling multiple campaigns simultaneously, often using disposable technologies to minimize cross-contamination. This agility is crucial for producing customized peptide sequences for orphan diseases and patient-specific cancer vaccines. The synergies between peptide and oligonucleotide manufacturing are becoming increasingly apparent, with many CDMOs offering both modalities to capture a larger share of the precision medicine market.
Key themes in the industry include integrated GMP peptide and oligonucleotide manufacturing platforms to support late-phase and commercial programs, as well as NCE development and generic API scale-up amid growing demand from GLP-1 and therapeutic API pipelines[reference:44]. Major companies such as Bachem, PolyPeptide, and CordenPharma are expanding their capabilities to meet this demand[reference:45].
The rise of personalized neoantigen vaccines represents a significant opportunity for peptide CDMOs. Clinical trials are exploring personalized synthetic long peptide vaccines in patients with advanced melanoma and renal cell carcinoma[reference:46]. These approaches require rapid, customized peptide synthesis capabilities that only specialized CDMOs can provide. The ability to manufacture patient-specific peptide sequences on demand is becoming a competitive differentiator in the CDMO landscape.
Looking ahead, the convergence of peptide and oligonucleotide technologies is expected to drive significant M&A activity in the sector. Companies that can offer integrated platforms spanning both modalities will be well-positioned to capture market share in the growing precision medicine space. The trend towards personalized medicine is not just a scientific advancement but a fundamental shift in how therapies are developed and delivered, creating lasting implications for the CDMO industry.